Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Development of an algorithm to identify individuals with Neurofibromatosis type 1 within administrative data.
General Neurology
P10 - Poster Session 10 (5:30 PM-6:30 PM)
6-001

To develop and validate an algorithm using health administrative data to accurately identify individuals with Neurofibromatosis 1 (NF1) living in Ontario, Canada (population ~14 million). 

 

 

NF1 is one of the most common autosomal dominant conditions; however, there is limited population-based data on individuals with NF1.

We identified individuals with NF1 using the Electronic Medical Records Primary Care Database (EMRPC or EMRALD). Records were included for individuals who were rostered, had a valid health card number and date of birth, had a physician visit within the last 2 years and were on the EMR for ≥1 year. We conducted a free-text search of commonly-used terms related to NF1 (i.e. neurofibroma, NF1, cafe-au-lait, Lisch, plexiform, freckling, MPNST, optic glioma). Records with > 1 term were reviewed by trained abstractors. An investigator with clinical NF1 expertise reviewed all records initially classified as definitive and possible, and performed final NF1 case allocation. Records not reviewed were assumed to not have NF1; we randomly sampled and abstracted 300 records with only one NF1 related term to confirm that our sampling strategy was unlikely to miss any cases. 

 

273,440 EMRPC records met criteria for abstraction. The free text search found 837 charts with >1 NF1-related terms. None of the randomly sampled charts with only 1 NF1-related term had NF1.  Validation has been completed in ~760 charts, with 61 definitive cases. This yields a preliminary minimum population-based prevalence of 1 in 4483. 

Strengths of this study include a large population based sample. The study is limited by the inability to capture individuals with NF1 who have not attended a primary care visit within the last 2 years.  After validation is complete, the algorithm will be applied to administrative data for the population of Ontario to study incidence, prevalence, mortality and health care utilization in individuals with NF.
Authors/Disclosures
Carolina Barnett Tapia, MD
PRESENTER
Dr. Barnett Tapia has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Barnett Tapia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Barnett Tapia has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Barnett Tapia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Barnett Tapia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NMD pharma. Dr. Barnett Tapia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Barnett Tapia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Dr. Barnett Tapia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Barnett Tapia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Barnett Tapia has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for argenx. The institution of Dr. Barnett Tapia has received research support from Department of defense. The institution of Dr. Barnett Tapia has received research support from Muscular dystrophy canada. The institution of Dr. Barnett Tapia has received research support from MgNet. The institution of Dr. Barnett Tapia has received research support from NIH. The institution of Dr. Barnett Tapia has received research support from Cartesian. The institution of Dr. Barnett Tapia has received research support from Alexion. Dr. Barnett Tapia has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file